Crown Bioscience

How do cancer cells become resistant to therapies that initially worked?

Cancer cells evolve and adapt to evade even advanced therapeutics, a process that preclinical models like organoids and multi-omics tools help researchers anticipate and prevent through better patient selection and combination strategies.

Why are organoids better than traditional cell culture or animal models?

Organoids are miniature 3D lab-grown tissues that mirror real human biology more closely than traditional 2D models or animal systems, allowing researchers to predict patient-specific drug responses with higher accuracy.

What role do biomarkers play in modern oncology drug development?

Biomarkers are central to shaping drug development and clinical trials by predicting therapeutic response and identifying optimal patient populations. The BCR-ABL biomarker in chronic myeloid leukemia exemplifies this power, raising five-year survival rates from 30-50% to over 90%.

How can AI accelerate drug discovery timelines?

AI cuts drug development time by nearly half while improving accuracy in identifying promising compounds, directly addressing soaring R&D costs and long development cycles that biotech companies face.

Why is KRAS such a difficult target and how are scientists approaching it?

KRAS was once considered undruggable, but nearly 90% of pancreatic cancers and 30-40% of lung and colorectal cancers harbor KRAS mutations. Recent FDA-approved KRAS G12C inhibitors mark progress, but resistance and diverse mutation profiles demand preclinical models and combination strategies to predict clinical response.